Do different formulations of botulinum toxin type A really have different migration characteristics? The dose units of the two main botulinum toxin A products are not equivalent, and there is continuing controversy about the appropriate dose conversion ratio. Cliff et al . 1 report on a study of anhidrotic halos after injections of Dysport and Botox to the forehead at a dose ratio of 3 : 1. The...

OBJECTIVE To define a safe and effective dose of Dysport for treating hip adductor spasticity. METHODS Patients with definite or probable multiple sclerosis, and disabling spasticity affecting the hip adductor muscles of both legs, were randomised to one of four treatment groups. Dysport (500, 1000, or 1500 Units), or placebo was administered by intramuscular injection to these muscles. Patie...

BACKGROUND Botulinum toxin A injections are indicated for the management of movement disorders, including upper limb spasticity. The aim of this study was to compare the cost per patient per injection for two botulinum toxin A preparations in 19 countries. METHODS Doses of botulinum toxin A are expressed in noninterchangeable units (U), ie, Botox(®) in 100 Allergan units (100 U) and Dysport(®...

BACKGROUND Botulinum neurotoxin type A (BoNT/A) is the active substance in preparations used for the highly effective treatment of neurologic disorders such as cervical dystonia, blepharospasm, or spasticity, as well as other indications such as axillary and palmar hyperhidrosis, and urologic disorders. OBJECTIVE To determine the amount of BoNT/A protein present in pharmaceutical preparations...

BACKGROUND Since the first comprehensive description of the physiologic effects of botulism toxicity in the 1820s, specific formulations of botulinum neurotoxin type A (BoNT-A) have been developed. Now, a new botulinum neurotoxin type A formulation (BoNTA-ABO; Dysport [abobotulinumtoxinA]; Medicis Aesthetics, Scottsdale, AZ) has been made available in the United States and these same physiologi...

PURPOSE To evaluate the costs and efficacy of type A botulinum toxin in the treatment of essential blepharospasm and hemifacial spasm. METHODS Pacients with essential blepharospasm and hemifacial spasm had their files analyzed. All patients were treated with type A botulinum toxin (Dysport) between April 2002 and May 2004 at the Oculoplastic Clinics of "Santa Casa de São Paulo". Twenty-seven ...

Background: Botulinum toxin type A has been shown to reduce the activity of glabellar muscles, decreasing the occurrence of expression-related facial lines. In April 2009, the U.S. Food and Drug Administration (FDA) approved a new formulation called Dysport. Objective: To evaluate the safety, efficacy, and duration of response of variable-dosed Dysport in the treatment of moderate to severe gla...

We aimed to compare Dysport (abobotulinumtoxinA, Ipsen Biopharm, Slough, UK) and Botox (onabotulinumtoxinA, Allergan, Irvine, CA, USA) at a 2.5:1 ratio in the treatment of cervical dystonia (CD). A Dysport/Botox ratio of lower than 3:1 was suggested as a more appropriate conversion ratio, considering its higher efficacy and more frequent incidence of adverse effects not only in the treatment of...

PURPOSE To evaluate the efficacy of intradetrusor Dysport (a type of botulinum toxin type A) injection in patients with idiopathic or neurogenic detrusor overactivity, who were refractory to antimuscarinic drugs, and to compare the efficacy of Dysport injection in both groups. MATERIALS AND METHODS Twelve patients with neurogenic detrusor overactivity (NDO) and 18 patients with idiopathic det...